Paediatric-onset inflammatory bowel disease (IBD) carries a doubled risk of developing cancer later in life, with skin, lymphoid, and gastrointestinal tumours of a particular concern, a study has found. The risk is higher in males and independent of IBD subtype and medical treatment.
Three years of adjuvant imatinib treatment is superior in efficacy vs 1-year use in patients with gastrointestinal stromal tumours (GIST) at high risk of recurrence post-surgery, according to the secondary analysis of the SSGXVIII/AIO* trial.
It appears that light-to-moderate alcohol consumption (LMAC) can lower the risks of prevalent and incident type 2 diabetes mellitus (T2DM) in individuals without nonalcoholic fatty liver disease (NAFLD), suggests a study. However, LMAC increases the risk of T2DM in those with NAFLD.
Transcutaneous neuromodulation (TN) at acupoint Zusanli (ST36) appears to be more potent than TN at posterior tibial nerve (PTN) in the treatment of constipation and its related symptoms and rectal sensation, a study has shown.
A recent study involving Chinese patients with nonalcoholic fatty liver disease (NAFLD) suggests that positive antihepatitis B core antibody (anti-HBc) is linked to cirrhosis and possibly hepatocellular carcinoma (HCC) and cirrhotic complications.
Gastroesophageal reflux disease (GERD) is a condition which develops when reflux of stomach contents causes troublesome symptoms and/or complications.1 Audrey Abella speaks with Dr Tan Chi Chiu, gastroenterologist and senior consultant, Gastroenterology & Medicine International at Gleneagles Medical Centre, Singapore, to discuss how GERD can be addressed in the primary care setting.
The anti-PD-1 inhibitor camrelizumab demonstrated superior efficacy over chemotherapy (CT) and a tolerable safety profile for advanced/metastatic oesophageal squamous cell carcinoma (OSCC) in Chinese patients, the ESCORT* trial suggests.
Use of adalimumab or infliximab in biologic-naïve patients with inflammatory bowel disease (IBD) delivers comparable rates of corticosteroid-free remission, as shown by a study presented at the Advances in Inflammatory Bowel Disease (AIBD) Conference 2019.